Ann: Update on Novartis Agreement, page-205

I guess the job adds for Novartis staff with stem cell experience weren't because Novartis were "preparing a takeover for MSB" then.

But even more to the point, Novartis have had a year to pore over the detailed results from the Covid ARDS trial and all the biomarker data and after doing their own statistical analysis they have concluded there is no good evidence that it had any efficacy better than whatever else they are working on. Or that it was unlikely to be worth doing follow up ARDS trials or for heart failure either apparently.

Sorry for you guys, but really the delays were ominous.
Go back and take a look at the latest presentation from Dr Perin without the rose tinted glasses on.

"Even though the results have not been corrected for multiplicity..."

Dr Perin effectively acknowledging they should in fact be corrected for multiplicity, and what happens when you do the correction?

The expert analysis

"The trial failed the primary endpoint, so we should stop right there..."